Loading…
Loading…
XNCR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for XNCR and 80,000+ other tickers.
See exactly how XNCR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for XNCR and 80,000+ other tickers.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi…
Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement toward FDA Accelerated Approval discussions in 1H 2027 and a phase 3 trial by late 2027. The company is expanding XmAb819 into other ENPP3+ solid tumors and progressing XmAb942 in phase 2b for ulcerative colitis, with interim data expected by end of 2026.
Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod